Daily Medication Pearl: Benralizumab (Fasenra)
Benralizumab (Fasenra) is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older and with an eosinophilic phenotype.
Medication Pearl of the Day: Benralizumab (Fasenra)
Indication: Benralizumabis an interleukin-5 receptor (IL-5Rα) alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older and with an eosinophilic phenotype.
Insight:
- Dosing: Administer by subcutaneous injection. Recommended dose is 30 mg every 4 weeks for the first 3 doses, followed by once every 8 weeks thereafter
- Dosage form: Injection 30 mg/mL solution in a single-dose prefilled syringe. Injection 30 mg/mL solution in a single dose autoinjector Fasenra Pen.
- Adverse events (AEs): Most common AEs are headache and pharyngitis.
- Mechanism of action: Benralizumab is a humanized afucosylated, monoclonal antibody (IgG1, kappa) that directly binds to the alpha subunit of the IL-5Rα with a dissociation constant of 11 pM.
- Manufacturer: AstraZeneca
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025